Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit
- Authors:
- Tomohiro Takehara
- Tetsuo Tani
- Hiroyuki Takiue
- Ryo Takeshita
- Arifumi Iwamaru
- Tatsuya Yamamoto
- Hidefumi Koh
View Affiliations
Affiliations: Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo 190‑8531, Japan , Division of Pulmonary Medicine, Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo 190‑8531, Japan, Department of Neuropsychiatry, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo 190‑8531, Japan, Department of Surgery, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo 190‑8531, Japan
- Published online on: January 10, 2020 https://doi.org/10.3892/mco.2020.1974
-
Pages:
273-277
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, and 4 patients had a mood disorder. There were 15 patients who were diagnosed using bronchoscopy. The histology indicated adenocarcinoma, squamous cell carcinoma and non‑small‑cell lung cancer‑not otherwise specified were in 11, 8, and 1 patient, respectively, while small‑cell lung cancer was indicated in 4 patients. Surgery, chemoradiotherapy, radiotherapy, chemotherapy was performed in 13, 4, 2, 1 and 4 patients, respectively. The median survival time was 76.7 months for patients who underwent surgery, while it was 14.4 months for those who underwent chemoradiotherapy. In the MPU, patients with lung cancer and severe psychiatric disorders could be safely diagnosed, and patients with early‑stage lung cancer exhibited long‑term survival.
View References
|
1
|
Siegel R, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
de Leon J and Diaz FJ: A meta-analysis of
worldwide studies demonstrates an association between schizophrenia
and tobacco smoking behaviors. Schizophr Res. 76:135–157.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Landow L, Szetela B and Know MA: Reducing
smoking among psychiatric inpatients: A survey of psychiatrists. Am
J Public Health. 85(1169)1995.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Catts VS, Catts SV, O'Toole BI and Frost
AD: Cancer incidence in patients with schizophrenia and their
first-degree relatives-A meta-analysis. Acta Psychiatr Scand.
117:323–336. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tran E, Rouillon F, Loze JY, Casadebaig F,
Philippe A, Vitry F and Limosin F: Cancer mortality in patients
with schizophrenia: An 11-year prospective cohort study. Cancer.
115:3555–3562. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Obuchi T, Okabayashi K, Imakiire T, Yoneda
S and Iwasaki A: Outcomes of surgery in lung cancer patients with
schizophrenia. Surg Today. 44:855–858. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Miyagawa S, Inoue Y and Higa K: Medical
and psychiatric treatment in liaison psychiatric ward of a general
hospital. Jap J General Hospital Psychiatry. 24:245–252. 2012.(In
Japanese).
|
|
8
|
Mateen FJ, Jatoi A, Lineberry TW,
Aranguren D, Creagan ET, Croghan GA, Jett JR, Marks RS, Molina JR
and Richardson RL: Do patients with schizophrenia receive
state-of-the-art lung cancer therapy? A brief report.
Psychooncology. 17:721–725. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Carpenter WT Jr, Strauss JS and Bartko JJ:
The diagnosis and understanding of schizophrenia. Part I. Use of
signs and symptoms for the identification of schizophrenic
patients. Schizophr Bull. 37–49. 1974.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fava GA, Wise TN, Molnar G and Zielezny M:
The medical-psychiatric unit: A novel psychosomatic approach.
Psychother Psychosom. 43:194–201. 1985.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Myrdal G, Gustafsson G, Lambe M, Horte LG
and Stahle E: Outcome after lung cancer surgery. Factors predicting
early mortality and major morbidity. Eur J Cardiothorac Surg.
20:694–699. 2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
British Thoracic Society; Society of
Cardiothoracic Surgeons of Great Britain and Ireland Working Party:
BTS guidelines: Guidelines on the selection of patients with lung
cancer for surgery. Thorax 56: 89-108, 2001.
|
|
13
|
Brunelli A, Kim AW, Berger KI and
Addrizzo-Harris DJ: Physiologic evaluation of the patient with lung
cancer being considered for resectional surgery: Diagnosis and
management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 143
(Suppl 5):e166S–e190S. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ferguson MK and Vigneswaran WT: Diffusing
capacity predicts morbidity after lung resection in patients
without obstructive lung disease. Ann Thorac Surg. 85:1158–1164;
discussion 1164-1165. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tisi GM: Preoperative evaluation of
pulmonary function. Validity, indications, and benefits. Am Rev
Respir Dis. 119:293–310. 1979.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yoon SM, Shaikh T and Hallman M:
Therapeutic management options for stage III non-small cell lung
cancer. World J Clin Oncol. 8:1–20. 2017.PubMed/NCBI View Article : Google Scholar
|
